| __timestamp | Iovance Biotherapeutics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 5758000 |
| Thursday, January 1, 2015 | 999000 | 8423000 |
| Friday, January 1, 2016 | 978000 | 11986000 |
| Sunday, January 1, 2017 | 952000 | 15215000 |
| Monday, January 1, 2018 | 956000 | 15356000 |
| Tuesday, January 1, 2019 | 8122999 | 16660000 |
| Wednesday, January 1, 2020 | 8712000 | 52459000 |
| Friday, January 1, 2021 | 13980000 | 75061000 |
| Saturday, January 1, 2022 | 21135000 | 87221000 |
| Sunday, January 1, 2023 | 10755000 | 83779000 |
Unlocking the unknown
In the dynamic world of biopharmaceuticals, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Supernus Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. from 2014 to 2023. Over this period, Supernus Pharmaceuticals consistently demonstrated a higher cost of revenue, peaking at approximately $87 million in 2022, a staggering 900% increase from 2014. In contrast, Iovance Biotherapeutics showed a more modest growth, with its cost of revenue reaching around $21 million in 2022, marking a 125% increase from its 2014 figures. This disparity highlights Supernus's aggressive expansion strategy, while Iovance maintains a more conservative approach. Understanding these trends provides valuable insights into each company's operational strategies and market positioning. As the biopharmaceutical landscape evolves, such analyses are crucial for investors and stakeholders aiming to make informed decisions.
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Takeda Pharmaceutical Company Limited vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Biogen Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Viatris Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.
Cost of Revenue Trends: ADMA Biologics, Inc. vs Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Supernus Pharmaceuticals, Inc. and Xencor, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.'s Expenses
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Evotec SE